Significance of Immunohistochemical Expression of Survivin in Renal Cell Carcinoma

May 5, 2021 updated by: Maisa Hashem Mohammed, Sohag University

A Retrospective Study

detection of Survivin expression in renal cell carcinoma and correlate this expression to tumor grade and stage.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

renal cell carcinoma is the third most prevalent malignant tumor of the genitourinary system. deregulation of apoptosis is involved in carcinogenesis by abnormally prolonged cell survival, facilitating accumulations of multiple mutations and augment resistance to immune-surveillance. Survivin is a member of inhibitor of Apoptosis Protein family (IAPs). it play a role in cell cycle regulation by inhibiting apiptosis. Survivin is over-expressed in many human neoplasms.

Study Type

Observational

Enrollment (Actual)

40

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Sohag, Egypt, 82524
        • Maisa Hashem Mohammed

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

30 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with symptoms and signs of renal neoplasms admitted to Sohag University hospital and underwent nephrectomy operations. excisional specimens sent to pathology Lab will be sectioned and stained by H&E. only cases of renal cell carcinoma will be included in the study.

Description

Inclusion Criteria:

  • patients suffer from renal cell carcinomas

Exclusion Criteria:

  • patients received pre-operative chemotherapy or radiotherapy. patients with insufficient clinical data.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
expression of survivin in neoplastic and adjacent normal renal tissues
Time Frame: april, 2021
Survivin is highly expressed in neoplastic renal tissues compared to normal ones by immunohistochemical measures..
april, 2021

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Investigators

  • Principal Investigator: Maisa H Mohammed, MD, a lecturer of pathology, Sohag faculty of medicine

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2020

Primary Completion (Actual)

June 30, 2020

Study Completion (Actual)

December 30, 2020

Study Registration Dates

First Submitted

April 30, 2021

First Submitted That Met QC Criteria

April 30, 2021

First Posted (Actual)

May 5, 2021

Study Record Updates

Last Update Posted (Actual)

May 7, 2021

Last Update Submitted That Met QC Criteria

May 5, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Soh-Med-21-04-28

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Renal Cell Carcinoma

Clinical Trials on sectioning and staining of renal neoplasms after nephrectomy operation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in China

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe